National Asset Management, Inc. Cyma Bay Therapeutics, Inc. Transaction History

National Asset Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 31, 2020	SELL	$1.41 - $4.25 $14,487 - $43,668	-10,275 Closed	0 $0
Q1 2020 May 06, 2020	SELL	$1.25 - $2.02 $6,937 - $11,211	-5,550 Reduced 35.07%	10,275 $16,000
Q4 2019 Feb 10, 2020	SELL	$1.33 - $5.93 $10,773 - $48,033	-8,100 Reduced 33.86%	15,825 $32,000
Q3 2019 Nov 12, 2019	BUY	$5.12 - $7.21 $5,120 - $7,210	1,000 Added 4.36%	23,925 $123,000
Q2 2019 Aug 05, 2019	BUY	$6.05 - $13.66 $138,696 - $313,155	22,925 New	22,925 $165,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.